Researchers target unfolded protein response in cancerous tumor growth.
Garber
Ken
K
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D015687:Cell Hypoxia; D002467:Cell Nucleus; D004721:Endoplasmic Reticulum / Q000378:metabolism*; D000091342:Endoplasmic Reticulum Chaperone BiP; D004722:Endoribonucleases; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006360:Heat-Shock Proteins / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D008562:Membrane Glycoproteins / Q000187:drug effects / Q000378:metabolism; D008565:Membrane Proteins / Q000187:drug effects; D018832:Molecular Chaperones / Q000187:drug effects* / Q000378:metabolism*; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D017510:Protein Folding; D017346:Protein Serine-Threonine Kinases / Q000187:drug effects; D014158:Transcription, Genetic; D019892:eIF-2 Kinase / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D000091342:Endoplasmic Reticulum Chaperone BiP; D004722:Endoribonucleases; D004791:Enzyme Inhibitors; D006360:Heat-Shock Proteins; D008562:Membrane Glycoproteins; D008565:Membrane Proteins; D018832:Molecular Chaperones; D017346:Protein Serine-Threonine Kinases; D019892:eIF-2 Kinase; C053387:endoplasmin; C403982:ERN2 protein, human